Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)
Status:
Active, not recruiting
Trial end date:
2022-02-08
Target enrollment:
Participant gender:
Summary
The purpose of this study was to evaluate the efficacy and safety of pembrolizumab plus
epacadostat compared to sunitinib or pazopanib in participants with locally
advanced/metastatic renal cell carcinoma (mRCC) with a clear cell component who have not
received prior systemic therapy for their mRCC.